Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $210.75 Average PT from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given an average rating of “Buy” by the nine ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $210.75.

A number of research analysts have commented on KRYS shares. Chardan Capital restated a “buy” rating and issued a $219.00 price objective on shares of Krystal Biotech in a research note on Tuesday, August 5th. Bank of America lowered their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a “buy” rating on the stock in a research report on Tuesday, July 22nd. Guggenheim reduced their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Friday, July 25th. Finally, Citigroup reissued a “neutral” rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th.

Krystal Biotech Price Performance

Shares of KRYS opened at $145.86 on Thursday. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $207.84. The stock has a market cap of $4.22 billion, a PE ratio of 29.65 and a beta of 0.70. The firm has a fifty day moving average price of $143.85 and a 200 day moving average price of $154.77.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million during the quarter, compared to analysts’ expectations of $95.42 million. As a group, equities analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares of the company’s stock, valued at $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 49,800 shares of company stock worth $7,487,943 over the last quarter. Company insiders own 13.70% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently bought and sold shares of KRYS. Public Sector Pension Investment Board raised its stake in shares of Krystal Biotech by 8.0% in the 2nd quarter. Public Sector Pension Investment Board now owns 86,688 shares of the company’s stock valued at $11,916,000 after acquiring an additional 6,424 shares during the period. Tower Research Capital LLC TRC grew its holdings in Krystal Biotech by 310.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,998 shares of the company’s stock valued at $412,000 after purchasing an additional 2,268 shares in the last quarter. E Fund Management Co. Ltd. grew its holdings in Krystal Biotech by 71.4% during the 2nd quarter. E Fund Management Co. Ltd. now owns 3,870 shares of the company’s stock valued at $532,000 after purchasing an additional 1,612 shares in the last quarter. Soleus Capital Management L.P. grew its holdings in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Finally, Shay Capital LLC acquired a new position in Krystal Biotech during the 2nd quarter worth $893,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).